Revelation starts Phase 1b Gemini CKD study; shareholders approve reverse split but reincorporation fails

REVELATION BIOSCIENCES, INC.

PRIME Phase 1b study of Gemini in Stage 3-4 CKD patients started; dosing mid-Feb, topline data expected mid-year.
Shareholders approved reverse stock split (range 1:2 to 1:50) with board discretion; 3.96M for, 163K against.
Change of domicile from Delaware to Nevada failed despite 97% of votes present in favor (2.96M for, 74K against) due to insufficient affirmative votes of outstanding shares.
Shareholders approved issuance of shares under warrants (Dec 2024) exceeding 20% threshold; also approved meeting adjournment.
1,089,301 broker non-votes affected the change-of-domicile and warrant issuance proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.